Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer

NCT00728663 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: cetuximab
DRUG: docetaxel

Sponsor

Swiss Cancer Institute